Bayesian monitoring of clinical trials with failure-time endpoints

被引:16
|
作者
Rosner, GL [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
clinical trials; Dirichlet process; Gibbs sampling; survival analysis;
D O I
10.1111/j.0006-341X.2005.031037.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article presents an aid for monitoring clinical trials with failure-time endpoints based on the Bayesian nonparametric analyses of the data. The posterior distribution is a mixture of Dirichlet processes in the presence of censoring if one assumes a Dirichlet process prior for the survival distribution. Using Gibbs sampling, one can generate random samples from the posterior distribution. With samples from the posterior distributions of treatment-specific survival curves, one can evaluate the current evidence in favor of stopping or continuing the trial based on summary statistics of these survival curves. Because the method is nonparametric, it can easily be used, for example, in situations where hazards cross or are suspected to cross and where relevant clinical decisions might be based on estimating when the integral between the curves might be expected to become positive and in favor of the new but toxic therapy. An example based on an actual trial illustrates the method.
引用
收藏
页码:239 / 245
页数:7
相关论文
共 50 条
  • [1] Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses
    Gu, MG
    Lai, TL
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (05): : 423 - 438
  • [2] Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years
    He, Pei
    Lai, Tze Leung
    Su, Zheng
    [J]. CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 103 - 112
  • [3] One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints
    Sofeu, Casimir Ledoux
    Emura, Takeshi
    Rondeau, Virginie
    [J]. STATISTICS IN MEDICINE, 2019, 38 (16) : 2928 - 2942
  • [4] Analysis of multivariate failure-time data from HIV clinical trials
    Walker, AS
    Babiker, AG
    Darbyshire, JH
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (02): : 75 - 93
  • [5] Bayesian semiparametric inference for the accelerated failure-time model
    Kuo, L
    Mallick, B
    [J]. CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE, 1997, 25 (04): : 457 - 472
  • [6] BAYESIAN PRIOR DISTRIBUTIONS FOR SYSTEMS WITH EXPONENTIAL FAILURE-TIME DATA
    FERTIG, KW
    [J]. ANNALS OF MATHEMATICAL STATISTICS, 1972, 43 (05): : 1441 - &
  • [7] Novel Endpoints for Heart Failure Clinical Trials
    Hamo C.E.
    Gheorghiade M.
    Butler J.
    [J]. Current Heart Failure Reports, 2017, 14 (4) : 210 - 216
  • [8] Bayesian design of multi-regional clinical trials with time-to-event endpoints
    Bean, Nathan William
    Ibrahim, Joseph George
    Psioda, Matthew Austin
    [J]. BIOMETRICS, 2023, 79 (04) : 3586 - 3598
  • [9] Selection of endpoints for heart failure clinical trials
    Zanolla, L
    Zardini, P
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (06) : 717 - 723
  • [10] Failure-time prediction
    Rissanen, J
    Shedler, G
    [J]. JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1998, 66 (02) : 193 - 210